Baird Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 58.3%

Neg 0% Neu 0% Pos 58.3%

Baird analyst Jack Allen maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $7 to $13.